

Viral Epidemiology Snapshot: December 28, 2025-January 3, 2026

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	1373	489	35.6%
Flu B	1373	77	5.6%
RSV	601	121	20.1%
CoV-2	724	70	9.7%


Bacterial Respiratory Infections (Molecular Tests)

Organism	#Tested	#Positive	% Positive
<i>Bordetella parapertussis</i>	308	0	0.0%
<i>Bordetella pertussis</i>	308	3	1.0%
<i>Chlamydia pneumoniae</i>	300	0	0.0%
<i>Mycoplasma pneumoniae</i>	300	1	0.3%

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	300	18	6.0%
Coronavirus 229E	300	5	1.7%
Coronavirus HKU1	300	2	0.7%
Coronavirus NL63	300	4	1.3%
Coronavirus OC43	300	2	0.7%
Metapneumovirus	300	13	4.3%
Rhinovirus/Enterovirus	300	56	18.7%
Parainfluenza 1	300	8	2.7%
Parainfluenza 2	300	3	1.0%
Parainfluenza 3	300	1	0.3%
Parainfluenza 4	300	4	1.3%

Flu, RSV, & CoV-2 Trends



Flu A Subtyping

2009 H1N1	3
Seasonal H1	0
Seasonal H3	50
No Subtype	436
Pending subtype	0

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8-week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

Flu, RSV, & CoV-2 Trends

